MARGATE, N.J.--April 11, 2003-- DaVinci(R) Introduces a Revolutionary Program for Health Care Professionals to Take the Guesswork Out of Designing Individualized Nutritional Supplement Regimens for Their Patients
GeneLink, Inc. (OTCBB:GNLK) announced today that DaVinci(R) Laboratories of Vermont, a division of FoodScience Corporation, is revolutionizing the way health care professionals design supplement programs for their patients.
In January 2003, DaVinci signed an agreement to distribute GeneLink's patented DNA Collection Kit(R) and Nutragenetic Profile Assessments(TM). DaVinci also designed a full line of comprehensive supplements that correspond with the test results provided by GeneLink.
GeneLink's Nutragenetic Profile(TM) testing is cutting edge technology and will allow Health Care Professionals to provide each patient with his/her own genetic profile using DNA from a simple swab of the cheek. This genetic profile will examine the natural, small variations given to us by our parents that exist in our genes, called Single Nucleotide Polymorphisms (SNPs).
The genetic profiles examine the following areas:Oxidative Stress, Heart & Circulatory Stress, Detoxification Function, Immune Health, and Bone Health.
There are three possible outcomes for each of the 7 areas tested. These outcomes are color-coded. Green means that this area of a person's genetic profile is balanced and only needs basic nutritional support. Yellow shows that there is a genetic weakness in the area and requires additional supplementation, and Red suggests a strong genetic weakness, which requires extra nutritional support.
Based on each outcome, there is an individualized GENEssentials(TM) nutritional supplement program that is recommended.
"There has been a dramatic increase in consumer awareness of the relationship between preventive health and nutritional therapies. GeneLink's Nutragenetic Profile Assessment(TM) outlines the patient's genetic strengths and weaknesses in seven important areas and DaVinci's GENEssentials Supplement Program allows the Health Care Professional to offer a very specific and individualized protocol of prevention therapy. Our innovative GENEssentials line coupled with GeneLink's technology has enormous positive implications; it gives our physicians the ability to better analyze and optimize their patient's health needs using preventive therapy," says Dale Metz, President of DaVinci Laboratories of Vermont.
GeneLink, Inc., (OTCBB:GNLK) a pioneer DNA banking and hereditary genetic information service, has developed a proprietary method for genetic assessments (patents pending) and is beginning to license its breakthrough Nutragenetic and Dermagenetic Profile Assessments(TM) to companies that market or manufacture products for the $100 billion plus skin care, nutritional supplement, and health care industries.
For more information about GeneLink, visit its website at www.genelink.info.
This press release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties.
Actual results could differ materially from those expressed in any forward-looking statement. GNLK disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.